Depression Treatment in Sarasota: Why Patients Are Looking Beyond Antidepressants

Roughly one in three people treated for major depression do not achieve adequate relief from their first antidepressant — and a significant portion continue to struggle even after trying a second or third medication. That clinical reality has driven a shift in how psychiatry approaches depression, and it is why patients in Sarasota and across the country are asking questions that go well beyond which SSRI to try next.

The Limits of First-Line Antidepressants

SSRIs — selective serotonin reuptake inhibitors — and SNRIs — serotonin-norepinephrine reuptake inhibitors — are the standard first-line medications for major depressive disorder. Research documents their efficacy clearly, and for many patients they provide meaningful, sustained relief (National Center for Biotechnology Information). The problem is not that these medications do not work. The problem is that they do not work for everyone, and the patients they do not help often go without an adequate explanation for why.

Several factors contribute to antidepressant non-response. Genetic variations in how individuals metabolize medications can render standard doses ineffective or poorly tolerated before they have a chance to work. Underlying medical conditions — thyroid dysfunction, chronic inflammation, sleep disorders — can sustain depressive symptoms independently of serotonin-targeted treatment. And for some patients, the biology of their depression involves neurological pathways that SSRIs and SNRIs do not directly address.

When antidepressants fall short, that is not a verdict on the patient. It is clinical information pointing toward a different mechanism. Our role at Cohen & Associates is to take that information seriously and look at what it suggests.

What Interventional Psychiatry Adds

Interventional psychiatry refers to the use of procedure-based treatments — tools like TMS and ketamine — alongside or in place of traditional medication management. At Cohen & Associates, Dr. Rebecca Cohen leads our interventional approach as a board-certified psychiatrist and psychopharmacologist with national recognition in transcranial magnetic stimulation. We offer a range of evidence-based options that go beyond the standard antidepressant classes.

For patients who have not responded to one or more antidepressant trials, two treatment options in particular have strong evidence behind them.

Transcranial magnetic stimulation (TMS) uses magnetic pulses to directly stimulate brain regions that are underactive in depression — bypassing the bloodstream entirely and acting on the neural circuitry involved in mood regulation. The National Institute of Mental Health has highlighted research supporting ketamine’s rapid antidepressant action for patients who have not responded to standard care (National Institute of Mental Health, 2024). TMS works through a different mechanism — neuroplasticity promotion — and the antidepressant benefits can persist well beyond the treatment course itself (National Center for Biotechnology Information).

Ketamine-assisted psychotherapy (KAP) acts on the glutamate system through NMDA receptor blockade — a mechanism entirely distinct from SSRIs and SNRIs — and has demonstrated rapid antidepressant effects in patients with treatment-resistant major depression (National Library of Medicine). The research supporting ketamine’s use in this population is substantial and continues to grow. At our practice, ketamine is delivered within a structured psychotherapy framework, not as a standalone infusion — the therapeutic integration is built into our protocol by design.

We also offer SPRAVATO® (esketamine nasal spray), the FDA-approved treatment for treatment-resistant depression in adults. SPRAVATO® is administered in our office under medical supervision and represents a distinct option from KAP for patients who meet the clinical criteria for treatment-resistant depression.

The Role of Evaluation and Pharmacogenomics

Before any advanced treatment is recommended, we conduct a comprehensive psychiatric evaluation. This is where we examine not just what has not worked, but why. For patients who have been through multiple medication trials without adequate relief, that history contains useful information — about dosing, duration, drug interactions, and metabolic factors that may have affected response.

In some cases, we recommend pharmacogenomic testing — genetic testing that examines how your body processes specific medications. This can clarify why certain antidepressants have not worked as expected and help guide more targeted medication selection going forward. It is one of the tools that distinguishes a full psychiatric evaluation from a standard medication management appointment.

Results vary by individual. We do not apply a single protocol to every patient presenting with depression, and we do not guarantee outcomes. What we do is take a thorough look at the full picture and give you an honest clinical assessment of what the evidence supports for your specific situation.

Addressing the Practical Barriers

Cost and access are two of the most common reasons patients delay seeking advanced psychiatric care, and we address both directly.

We operate on a direct-care model, which means we do not bill insurance and do not accept insurance payments at the time of service. Patients pay by debit/credit card, check, or cash. This model removes insurance companies from the clinical decision-making process, which we believe produces better care — but we do not minimize the financial question. Visits may be partially covered by your insurance as out-of-network care, and we provide invoices for patient-submitted reimbursement on request. For patients considering TMS, insurance coverage may apply depending on your plan and clinical presentation; our team verifies coverage specifics before treatment begins.

Scheduling concerns are also real. A TMS course involves sessions five days per week for approximately six weeks — a time commitment that requires planning. Each session at our practice runs in as little as three minutes, with a range of three to twenty minutes, and you can drive yourself and return to work immediately after. KAP sessions have a different time profile, which we discuss during the evaluation. Both in-person and telehealth appointments are available depending on the nature of the visit.

We see patients Monday through Thursday from 9 AM to 5 PM and Friday from 9 AM to 1 PM at our Sarasota location. Discuss your scheduling needs directly with our team — we work with patients to make care accessible.

FAQ

How many antidepressants do I need to have tried before considering TMS or KAP?

TMS for major depressive disorder requires a history of inadequate response to at least one prior antidepressant at an adequate dose. The clinical designation of treatment-resistant depression — which is relevant to both SPRAVATO® eligibility and KAP candidacy — typically involves inadequate response to two or more antidepressant trials. Your evaluation will determine where you fall and which options are clinically appropriate.

Can I continue my current antidepressant while undergoing TMS or KAP?

In many cases, yes. TMS is frequently used alongside existing medication, and some patients continue their antidepressants throughout a KAP course. Whether to maintain, adjust, or taper existing medications is a clinical decision made on an individual basis during your evaluation. Discuss your current regimen with your provider before making any changes.

What if I’ve had bad experiences with medication side effects?

That history is important and directly relevant to your evaluation. TMS is a non-medication treatment with no systemic drug burden, and its side effect profile is substantially different from antidepressants. For patients who have had to stop medications due to tolerability issues, TMS may be particularly worth exploring. Bring your full medication history — including side effects — to your evaluation appointment.

Is pharmacogenomic testing covered by insurance?

Coverage for pharmacogenomic testing varies by plan. Our team can discuss the practical details during your evaluation if testing is recommended for your situation.

Are there options beyond TMS and KAP for treatment-resistant depression?

Yes. SPRAVATO® — the FDA-approved esketamine nasal spray for treatment-resistant depression — is another option available at our practice. Medication augmentation strategies, in which a second medication is added to an existing antidepressant, may also be appropriate for some patients. Your evaluation will map out the full range of relevant options for your specific clinical picture.

Key Takeaways

• A significant proportion of patients with major depression do not achieve adequate relief from first- or second-line antidepressants — this is a clinical signal, not a personal failing.
• Interventional psychiatry options, including TMS and KAP, operate through different mechanisms than SSRIs and SNRIs and may help patients who have not responded to conventional medication.
• Cohen & Associates offers TMS, KAP, SPRAVATO®, pharmacogenomic evaluation, and comprehensive medication management within a single interventional psychiatry practice in Sarasota.
• A thorough psychiatric evaluation — including review of prior treatment history — is the essential first step before any advanced treatment recommendation.
• Results vary by individual; we discuss realistic expectations based on your specific history and presentation, not generalized statistics.

A history of antidepressants that have not worked is exactly the kind of history our evaluation process is built to assess. At Cohen & Associates, we will tell you plainly what that history suggests and what options make sense to explore next. Call us at 941-559-8500 or use our online contact form to schedule a new patient evaluation.

References

1. National Center for Biotechnology Information. SSRIs — efficacy and limitations. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
2. National Institute of Mental Health. New hope for rapid-acting depression treatment (2024). https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
3. National Library of Medicine. Antidepressant efficacy of ketamine in treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/23982301/
4. National Center for Biotechnology Information. TMS therapy and neuroplasticity. https://pmc.ncbi.nlm.nih.gov/articles/PMC9313265/

Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Depression treatment, including advanced options such as TMS, ketamine-assisted psychotherapy, and SPRAVATO®, should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Individual results vary. SPRAVATO® is a prescription medication available only through certified healthcare settings. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.